IL17A and myasthenia gravis: Given the complexity of Th17-mediated inflammation, subsequent investigations should concentrate on elucidating the detailed mechanisms and therapeutic implications of modulating the IL-17 pathway in MG (Sun et al., 2019; Ashida et al., 2021; Cebi et al., 2023).